Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)Christian F. Singer, Michael Gnant, Rupert Bartsch et al.|European Journal of Cancer|2020Cited by 52
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter Dubsky, Martin Filipits, Christian F. Singer et al.|European Journal of Cancer|2020Cited by 52
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupLisa Pleyer, Richard Greil, Hartmut Döhner et al.|International Journal of Molecular Sciences|2017Cited by 51
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F. Singer, Georg Pfeiler et al.|British Journal of Cancer|2021Cited by 16
Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.Christian F. Singer, Michael Gnant, Dominik Hlauschek et al.|Journal of Clinical Oncology|2024Cited by 6